Retatrutide Dosage Guide: Triple Agonist Protocol, Reconstitution & Syringe Units

Retatrutide research dosing overview: triple GLP-1/GIP/glucagon agonist mechanism, Phase 2 escalation protocol, reconstitution ratios, and syringe unit calculator.

TL;DR — Key Takeaways

• Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors — the only compound of its kind in clinical development.
• Phase 2 trial participants on the 12 mg/week dose lost an average of 24.2% body weight over 48 weeks.
• Standard research protocol: start at 2 mg/week, escalate slowly to 8–12 mg over 12+ weeks to manage GI side effects.
• Comes as lyophilized powder — must be reconstituted with bacteriostatic water before use.
• Use the free reconstitution calculator to get exact syringe units for any vial/dose combo.

Important Disclaimer: All information in this article is strictly for educational and research purposes. Retatrutide is an investigational compound and is not approved by the FDA or any regulatory agency for human use. Nothing here constitutes medical advice, a recommendation to use any compound, or a treatment protocol. Researchers must comply with all applicable laws and regulations. Consult a qualified healthcare professional before making any health-related decisions.

Retatrutide has generated significant attention in the research community since Phase 2 clinical trial data showed substantial reductions in body weight — results that outpaced earlier GLP-1 agents like semaglutide and tirzepatide in head-to-head trial comparisons. What makes Retatrutide mechanistically distinct is that it operates across three receptor systems simultaneously, rather than one or two.

This guide covers what Retatrutide is, how it differs from related compounds, the dosing patterns observed in published clinical research, and how to use the Peptide Performance Calculator to handle the reconstitution math accurately.

What Is Retatrutide?

Retatrutide (LY3437943) is a once-weekly injectable peptide developed by Eli Lilly. It is a triple agonist that activates three distinct hormone receptors:

• GLP-1 receptor (glucagon-like peptide-1) — regulates appetite, slows gastric emptying, improves insulin sensitivity
• GIP receptor (glucose-dependent insulinotropic polypeptide) — enhances insulin secretion, plays a role in fat storage and energy metabolism
• Glucagon receptor — promotes hepatic fat oxidation and energy expenditure, increases basal metabolic rate

The combination of all three pathways in a single molecule is what differentiates Retatrutide from semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual agonist). In the Phase 2 TRIUMPH-1 trial published in the New England Journal of Medicine (2023), participants receiving the highest dose of Retatrutide lost an average of 24.2% of body weight over 48 weeks — a figure that drew considerable interest from both clinical researchers and the broader research community.

How Retatrutide Differs From Semaglutide and Tirzepatide

The glucagon receptor component is the key differentiator. While glucagon is classically associated with raising blood glucose (which might seem counterproductive), selective glucagon receptor activation at the doses seen in Retatrutide trials appears to increase energy expenditure and drive hepatic fat oxidation without producing problematic hyperglycemia — particularly when co-administered with GLP-1 receptor agonism.

Typical Research Dosing Patterns

The dosing patterns described here are drawn from published clinical trial data and are presented for educational purposes only. They reflect what has been studied in controlled research settings, not recommendations for self-administration.

Escalating Dose Protocol (From Phase 2 Trial Data)

Clinical research on Retatrutide has consistently used a slow dose-escalation approach to manage gastrointestinal side effects (the primary adverse events observed). The general structure from published research:

• Weeks 1–4: 2 mg once weekly (initiation dose)
• Weeks 5–8: 4 mg once weekly
• Weeks 9–12: 8 mg once weekly
• Week 13+: Maintenance at 8 mg, 12 mg, or higher per protocol design

In the TRIUMPH-1 trial, participants were randomized to maintenance doses of 4 mg, 8 mg, or 12 mg per week. The 12 mg cohort showed the greatest weight reduction outcomes.

Key Observations from Published Research

• Administration is subcutaneous (under the skin), typically in the abdomen, thigh, or upper arm
• Once-weekly dosing due to the compound's long half-life (~6 days)
• Dose escalation is considered important for GI tolerability — rapid escalation correlates with higher rates of nausea and vomiting
• Effects on appetite and food intake were observed within the first two weeks of dosing in most study participants

How Reconstitution Works

Retatrutide in a research context is typically supplied as a lyophilized (freeze-dried) powder in sealed vials. Before use, the powder must be reconstituted by adding bacteriostatic water (BAC water) to create a solution.

Core Concepts

Lyophilized powder is stable at room temperature or refrigerated temperatures for extended periods. Once reconstituted with BAC water, the solution should be refrigerated and used within the manufacturer-specified window (typically 28–56 days, depending on the vial).

Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth in the reconstituted solution. Standard sterile water should not be substituted if multi-dose use is intended.

The Reconstitution Formula

Example: 10 mg vial + 2 mL BAC water

To find the injection volume for a given dose:

Example: 8,000 mcg (8 mg) dose at 5,000 mcg/mL

Example Reconstitution Scenarios

Scenario 1: 10 mg Vial + 2 mL BAC Water

Scenario 2: 10 mg Vial + 4 mL BAC Water

Using a higher water volume reduces concentration and increases injection volume, which some researchers prefer for higher doses to avoid sub-optimal absorption from a single high-volume injection site.

All values are for educational and calculator demonstration purposes only.

Note on injection volume: Subcutaneous injection volumes above 1–2 mL per single site are generally not recommended in clinical practice. Researchers working with higher doses typically split the injection across two sites or use a more concentrated reconstitution.

Using the Peptide Performance Calculator for Retatrutide

The Peptide Performance Reconstitution Calculator handles all of the above math automatically. To use it for a Retatrutide setup:

1. Enter your vial size — for a 10 mg vial, enter 10 in the mg field.
2. Enter BAC water volume — if you added 2 mL, enter 2.
3. Enter your target dose — for an 8 mg dose, enter 8000 mcg (or use the dosage converter if your calculator supports direct mg entry).
4. Select syringe type — for doses above 1 mL, select a standard 2 mL or 3 mL syringe rather than a U-100 insulin syringe.
5. The calculator returns the injection volume in mL and the corresponding syringe draw level.

For dose-to-volume conversion without reconstitution math, use the Dosage Calculator directly.

You can also view the full Retatrutide research profile in the Peptide Performance Database, which includes mechanism of action, evidence level, storage notes, and stacking considerations.

Storage and Stability Notes

• Unreconstituted powder: Store at 2–8°C (refrigerated) or as specified by the supplier. Avoid freeze-thaw cycles.
• Reconstituted solution: Refrigerate at 2–8°C. Use within the supplier-specified window. Do not freeze.
• Protect from direct light. Keep the vial sealed when not in use.
• Record the date of reconstitution on the vial.

Conclusion

Retatrutide represents an evolution in GLP-1 based research compounds — the addition of glucagon receptor agonism creates a mechanistically distinct profile that has produced noteworthy results in Phase 2 trials. For researchers working with this compound, accurate reconstitution math is a prerequisite for meaningful data.

Use the Peptide Performance Calculator to calculate your injection volumes and syringe units precisely, save your setup for each research session, and eliminate arithmetic errors from your workflow.

Frequently Asked Questions About Retatrutide

Q: What is Retatrutide? A: Retatrutide (LY3437943) is an investigational injectable peptide developed by Eli Lilly that simultaneously activates three hormone receptors: GLP-1, GIP, and glucagon. This triple agonist mechanism distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP), and it is currently the only compound of its kind in advanced clinical development. Phase 2 trial data published in the New England Journal of Medicine (2023) showed mean weight loss of 24.2% over 48 weeks at the highest dose.

Q: How does Retatrutide compare to semaglutide and tirzepatide? A: Retatrutide adds glucagon receptor agonism on top of the GLP-1/GIP dual agonism seen with tirzepatide. The glucagon component promotes hepatic fat oxidation and increases basal energy expenditure, which may explain the superior weight loss outcomes observed in Phase 2 trials — approximately 24% for Retatrutide vs. approximately 22.5% for tirzepatide at equivalent durations. However, Retatrutide remains investigational and is not approved for any use, while tirzepatide and semaglutide are both FDA-approved.

Q: What is the typical Retatrutide research dose? A: Phase 2 trial data shows an escalating protocol starting at 2 mg once weekly for the first 4 weeks, advancing to 4 mg at week 5, then 8 mg at week 9, with maintenance doses of 8–12 mg per week thereafter. The 12 mg/week cohort showed the greatest weight reduction in the TRIUMPH-1 trial. Slow escalation is critical to manage GI side effects, which are the primary adverse events observed.

Q: How do you reconstitute Retatrutide? A: Retatrutide is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water (BAC water) before use. For a 10 mg vial, adding 2 mL of BAC water creates a 5,000 mcg/mL concentration. For higher doses (8–12 mg), injection volumes will exceed 1 mL, so a standard 2–3 mL syringe is required rather than a U-100 insulin syringe. Always inject the BAC water slowly down the side of the vial, swirl gently, and refrigerate after reconstitution.

Q: What are the main differences between triple and dual GLP-1 agonists? A: Dual agonists like tirzepatide target the GLP-1 and GIP receptors, while triple agonists like Retatrutide add glucagon receptor activation. The glucagon receptor component drives increased hepatic fat oxidation and raises basal metabolic rate — effects that are additive to the appetite suppression and insulin sensitization from the GLP-1 and GIP pathways. Triple agonism produces a more complex metabolic profile with potentially greater energy expenditure, though it also introduces a more intricate safety and tolerability profile to manage.

For educational and research purposes only. Retatrutide is an investigational compound not approved for human use. Nothing in this article constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any health-related decisions.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions